Continuous Ambulatory Peritoneal Dialysis in Uremic Diabetics

  • Elias V. Balaskas
  • Dimitrios G. Orepoulos

Abstract

During the last 15 years, there has been an impressive increase in the number of patients with end-stage renal disease (ESRD) due to diabetic nephropathy [1]. Diabetic nephropathy has become the leading cause of ESRD in such countries as United States, Canada, Japan, Scandinavia and much of Western Europe, accounting for 30% of new patients and 26% of U.S. dialysis and transplant patients [2,3]. Hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD) and renal transplantation are standard therapies for these patients. Despite encouraging results with renal transplantation which offers a better quality of life and perhaps longer survival than dialysis [4,5], the majority are treated with dialysis, mainly because of the advanced age of most diabetics and the lack of kidney donors. When transplant is not available or is not medically feasible, dialysis therapy becomes inevitable for many of these patients, waiting for renal transplant. The choice of dialysis therapy depends on such factors as nephrologist’s bias, existence of extrarenal disease in the patient, treatment availability and other medical and social factors [2]. CAPD, which offers some advantages in the diabetic, was proposed, from early on, as the preferred dialytic treatment [6]. Now, CAPD is the first choice in dialytic treatment for ESRD in diabetes in Australia, New Zealand, England, Canada and some regions of the United States [2].

Keywords

Diabetic Nephropathy Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Residual Renal Function United States Renal Data System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    United States Renal Data System 1994 Annual Data Report. IV. Incidence and causes of treated ESRD. Am J Kidney Dis 1994; 24: Suppl. 2: S48–S56.Google Scholar
  2. 2.
    Markell MS, Friedman EA. Diabetic nephropathy: Management of the end-stage patient. Diabetes Care 1992; 15: 1226–1238.PubMedGoogle Scholar
  3. 3.
    D’Amico G. Comparability of the different registries on renal replacement therapy. Am J Kidney Dis 1995; 25: 113–118.PubMedGoogle Scholar
  4. 4.
    Mattern WD, McGaghie WC, Rigby RJ, Nissenson AR, Dunhan CB, Khayrallah MA. Selection of ESRD treatment: An international study. Am J Kidney Dis 1989; 13: 457–464.PubMedGoogle Scholar
  5. 5.
    Passlick J, Grabensee B. CAPD and transplantation in diabetics. Clin Nephrol 1988; 30: Suppl. 1: S18–S23.PubMedGoogle Scholar
  6. 6.
    Amair P, Khanna R, Leibel B, Pierratos A, Vas S, Meema E, Blair G, Chisolm L, Vas M, Zingg W, Digenis G, Oreopoulos DG. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease. N Engl J Med 1982; 306: 625–630.PubMedGoogle Scholar
  7. 7.
    Khanna R. Dialysis considerations for diabetic patients. Kidney Int 1993; 43: Suppl. 40: S58–S64.Google Scholar
  8. 8.
    Markell MS, Friedman EA. Care of the diabetic patient with end-stage renal disease. Sem Nephrol 1990; 10: 274–286.Google Scholar
  9. 9.
    Cardella CJ. Peritoneal dialysis and renal transplantation. Perit Dial Bull 1985; 5: 149–151.Google Scholar
  10. 10.
    Johnston JR. Maintaining diabetic patients on long-term peritoneal dialysis. Sem Dial 1995; 8: 390–394.Google Scholar
  11. 11.
    Holley JL. Psychological factors causing technique failure in continuous peritoneal dialysis: The patient and the health care providers. Sem Dial 1995; 8: 395–396.Google Scholar
  12. 12.
    Balaskas EV, Yuan ZY, Gupta A, Meema HE, Blair G, Bargman J, Oreopoulos DG. Long-term continuous ambulatory peritoneal dialysis in diabetics. Clin Nephrol 1994; 42: 54–62.PubMedGoogle Scholar
  13. 13.
    Kemperman FAW, van Leusen R, van Liebergen FJHM, Oosting J, Boeschoten EW, Struijk DG, Krediet RT, Arisz L. Continuous ambulatory peritoneal dialysis (CAPD) in patients with diabetic nephropathy. Neth J Med 1991; 38: 236–245.PubMedGoogle Scholar
  14. 14.
    Rottembourg J, Issad B, Allouache M, Baumelou A, Deray G, Jacobs C. Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients. Perit Dial Int 1989; 9: 289–294.PubMedGoogle Scholar
  15. 15.
    Viglino G, Cancarini GC, Catizone L, Cocchi R, De Vecchi A, Lupo A, Salomone M, Segoloni GP, Giangrande A. Ten years experience of CAPD in diabetics: comparison of results with non-diabetics. Nephrol Dial Transplant 1994; 9: 1443–1448.PubMedGoogle Scholar
  16. 16.
    United States Renal Data System 1994. Annual Data Report. VI. Patient Survival. Am J Kidney Dis 1994; 24: Suppl. 2: S76–S87.Google Scholar
  17. 17.
    United States Renal Data System 1994. Annual Data Report. VII. Causes of Death. Am J Kidney Dis 1994; 24: Suppl. 2: S88–S95.Google Scholar
  18. 18.
    Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994; 9: 280–286.PubMedGoogle Scholar
  19. 19.
    Zimmerman SW, Johnson CA, O’Brien M. Long-term survivors on peritoneal dialysis. Am J Kidney Dis 1987; 10: 241–249.PubMedGoogle Scholar
  20. 20.
    Lameire N, Bernaert P, Lambert MC, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46: Suppl. 48: S31–S38.Google Scholar
  21. 21.
    Maiorca R, Vonesh E, Cancarini GC, Cantaluppi A, Manili L, Brunori G, Camerini C, Feller P, Strada A. A six-year comparison of patient and technique survivals in CAPD and HD. Kidney Int 1988; 34: 518–524.PubMedGoogle Scholar
  22. 22.
    Khanna R, Oreopoulos DG. Peritoneal access for chronic peritoneal dialysis. Int J Artif Organs 1985; 8: 1–6.PubMedGoogle Scholar
  23. 23.
    Khanna R, Nolph KD, Oreopoulos DG. »Peritoneal Access.« In The Essentials of Peritoneal Dialysis, Chapter 2. Khanna R, Nolph KD, Oreopoulos DG, eds. Dordrecht: Kluwer Academic Publishers, 1993; pp 19–34.Google Scholar
  24. 24.
    Balaskas EV, Oreopoulos DG. »Continuous ambulatory peritoneal dialysis in uremic diabetics.« In The Kidney and Hypertension in Diabetes Mellitus, 2nd ed, Mogensen CE, ed. Boston, Dordrecht, London: Kluwer Academic Publishers, 1994; pp 469–485.Google Scholar
  25. 25.
    Hain H, Kessel M. Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transplant 1987; 2: 67–72.PubMedGoogle Scholar
  26. 26.
    Scarpioni LL, Ballocchi S, Castelli A, Cecchettin M, Poisetti PG. Continuous ambulatory peritoneal dialysis in diabetic patients. Contrib Nephrol 1990; 84: 60–74.PubMedGoogle Scholar
  27. 27.
    Levey AS. Nephrology forum: measurement of renal function in chronic renal disease. Kidney Int 1990; 38: 167–184.PubMedGoogle Scholar
  28. 28.
    Viberti G, Wiseman MJ, Pinto JR, Messent J. »Diabetic Nephropathy.« In Joslin’s Diabetes Mellitus, 13th ed, Kahn CR, Weir GC, eds. Philadelphia: Lea and Febiger, 1994; pp 691–737.Google Scholar
  29. 29.
    Khanna R, Nolph KD, Oreopoulos DG. »Peritoneal Dialysis in Diabetics.« In The Essentials of Peritoneal Dialysis, Khanna R, Nolph KD, Oreopoulos DG, eds. Dordrecht: Kluwer Academic Publishers, 1993; pp 99–108.Google Scholar
  30. 30.
    Tzamaloukas AH, Oreopoulos DG. Subcutaneous versus intraperitoneal insulin in the management of diabetes on CAPD: A review. Adv Perit Dial 1991; 7: 81–85.PubMedGoogle Scholar
  31. 31.
    Yuan ZY, Balaskas EV, Gupta A, Bargman JM, Oreopoulos DG. Is CAPD or Haemodialysis better? CAPD is more advantageous. Sem Dial 1992; 5: 181–188.Google Scholar
  32. 32.
    Khanna R. »Peritoneal dialysis in diabetic end-stage renal disease.« In The Textbook of Peritoneal Dialysis, Gokal R, Nolph KD, eds. Dordrecht: Kluwer Academic Publishers, 1994; pp 639–659.Google Scholar
  33. 33.
    Zingg W, Shirriff JM, Liebel B. Experimental routes of insulin administration. Perit Dial Bull 1982; 2: 24–27.Google Scholar
  34. 34.
    Duckworth WC. Insulin degradation: Mechanisms, products and significance. Endocrine Rev 1988; 9:319–345.Google Scholar
  35. 35.
    Rubin J, Bell AH, Andrews M, Jones Q, Olanch A. Intraperitoneal insulin: a dose response curve. ASAIO Trans 1989; 35: 17–21.PubMedGoogle Scholar
  36. 36.
    Rubin J, Reed V, Adair C, Bower J, Klein E. Effect of intraperitoneal insulin on solute kinetics in CAPD. Am J Med Sci 1986; 291: 81–87.PubMedGoogle Scholar
  37. 37.
    Wideroe T, Smedy LC, Berg KJ, Jorstad S, Svartas IM. Intraperitoneal insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 1983; 23: 22–28.PubMedGoogle Scholar
  38. 38.
    Madden MA, Zimmerman SW, Simpson DP. CAPD in diabetes mellitus: the risks and benefits of intraperitoneal insulin. Am J Nephrol 1982; 2: 133–139.PubMedGoogle Scholar
  39. 39.
    Twardowski ZJ, Nolph KD, McGary TJ, Moore HL. Influence of temperature and time on insulin absorption to plastic bags. Am J Hosp Pharm 1983; 40: 583–586.PubMedGoogle Scholar
  40. 40.
    Saudek CD, Salem JL, Pitt HA, Waxman K, Rubio M, Jean Didier N, Turner D, Fischell RE, Charles MA. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med 1989; 321: 574–579.PubMedGoogle Scholar
  41. 41.
    Schmitz O. Insulin-mediated glucose uptake in non-dialyzed and dialyzed uremic insulin dependent diabetic subjects. Diabetes 1985; 34: 1152–1159.PubMedGoogle Scholar
  42. 42.
    Grefberg N, Danielson BG, Nilson P, Berne C. Decreasing insulin requirements in CAPD patients given intraperitoneally insulin. J Diabetic Compl 1987; 1: 16–19.Google Scholar
  43. 43.
    Selam JL, Kashyap M, Alberti KGMM, Lozano J, Hanna M, Turner D, Jean Didier N, Chan E, Charles MA. Comparison of intraperitoneal and subcutaneous insulin administration on lipids apolipoproteins, fuel metabolites, and hormones in Type I diabetes mellitus. Metabolism 1989; 38: 908–912.PubMedGoogle Scholar
  44. 44.
    Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin dependent diabetes mellitus. Metabolism 1988; 37: 15–21.PubMedGoogle Scholar
  45. 45.
    Duckworth WC, Saudek CD, Henry RR. Why intraperitoneal delivery of insulin with implantable pump in NIDDM? Diabetes 1992; 41: 657–661.PubMedGoogle Scholar
  46. 46.
    Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: The White Hall study. Lancet 1983; i: 1373–1376.Google Scholar
  47. 47.
    Schade DS, Duckworth WC. In search of the subcutaneous insulin degradation syndrome. N Engl J Med 1986; 315: 147–153.PubMedGoogle Scholar
  48. 48.
    Henderson IS, Patterson KR, Loung ACT. Decreased intraperitoneal insulin requirements during peritonitis on continuous ambulatory peritoneal dialysis. BMJ 1985; 290: 1474.PubMedGoogle Scholar
  49. 49.
    Wanless IR, Bargman JM, Oreopoulos DG, Vas SL. Subcapsular steatonecrosis in response to peritoneal insulin delivery: A clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol 1989; 2: 69–74.PubMedGoogle Scholar
  50. 50.
    Harrison NA, Rainford DJ. Intraperitoneal insulin and the malignant omentum syndrome (Abstract). Nephrol Dial Transplant 1988; 3: 103.PubMedGoogle Scholar
  51. 51.
    Scalamogna A, Castelnova C, Crepaldi M, Guerra L, Graziani G, Cantaluppi A, Ponticelli C. Incidence of peritonitis in diabetic patients on CAPD: Intraperitoneal vs. subcutaneous insulin therapy. Adv Peri Dial 1987; 3: 166–170.Google Scholar
  52. 52.
    »A survey of diabetics in the CAPD/CCPD population.« In Continuous Ambulatory Peritoneal Dialysis in the USA, Lindblad AS, Novak JW, Nolph KD, Stablein DM, Culter SJ, Steinberg SM, Vena DA, eds. Dordrecht: Kluwer Academic Publishers, 1989; pp 63–74.Google Scholar
  53. 53.
    Gundersen T, Kjekhus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983; 6: 285–290.PubMedGoogle Scholar
  54. 54.
    Kjekhus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1989; 11: 43–50.Google Scholar
  55. 55.
    Nesto RW, Zarich SW, Jacoby RM, Kamalesh M. »Heart disease in diabetics.« In Joslin’s Diabetes Mellitus, 13th ed, Kahn CR, Weir GC, eds. Philadelphia: Lea and Febiger, 1994; pp 836–851.Google Scholar
  56. 56.
    Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease (editorial). N Engl J Med 1989; 321: 183–185.PubMedGoogle Scholar
  57. 57.
    DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: A multi-center randomized controlled clinical trial. Diabetes 1989; 38: 491–498.Google Scholar
  58. 58.
    Young MA, Nolph KD, Dutton S, Prowant BF. Anti-hypertensive drug requirements in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1984; 4: 85–88.Google Scholar
  59. 59.
    Di Paolo B, Di Liberate L, Fiederling B, Stuard S, Marini A, Bucciarelli S, Santoferrara A, Santarelli P, Albertazzi A. Incidence and pathophysiology of hypertension in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13: Suppl. 2: S396–S398.PubMedGoogle Scholar
  60. 60.
    Stablein DM, Hamburger RJ, Lindbland AS, Nolph KD, Novak JW. The effect of CAPD on hypertesion control; a report of the National CAPD registry. Perit Dial Int 1998; 8: 141–144.Google Scholar
  61. 61.
    Churchill DN. Adequacy of peritoneal dialysis: How much dialysis do we need? Kidney Int 1994; 46: Suppl. 48: S2–S6.Google Scholar
  62. 62.
    Rottembourg J, Issad B, Poignet JL, Stripoli P, Balducci A, Slama G, Gahl GM. »Residual renal function and control of blood glucose levels in insulin-dependent diabetic patients treated by CAPD.« In Prevention and Treatment of Diabetic nephropathy, Keen H, Legrain M, eds. Boston, Lancaster: MTP Press Ltd, 1983; pp 339–359.Google Scholar
  63. 63.
    Rottembourg J, Issad B, Allouache M, Jacobs C. Recovery of renal function in patients treated by CAPD. Adv Perit Dial 1989; 5: 63–66.PubMedGoogle Scholar
  64. 64.
    Shekkarie MA, Port FK, Wolfe RA, Guire K, Humphrys R, van Amburg G, Ferguson CW. Recovery from end-stage renal disease. Am J Kidney Dis 1990; 15: 61–65.Google Scholar
  65. 65.
    Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43: Suppl. 40: S106–S110.Google Scholar
  66. 66.
    Herbelin A, Nguyen AT, Zingraft J, Urena P, Descamps-Latscha B. Influence of uremia and haemodialysis on circulating interleukin-1 and tumour necrosis factor alpha. Kidney Int 1990; 37: 116–125.PubMedGoogle Scholar
  67. 67.
    Shah AH. Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989; 35: 1093–1106.PubMedGoogle Scholar
  68. 68.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.PubMedGoogle Scholar
  69. 69.
    Rottembourg J, Remaoun M, Maiga K, Bellio P, Issad B, Boudjemma A, Cossette PY. Continuous ambulatory peritoneal dialysis in diabetic patients. The relationship of hypertension to retinopathy and cardiovascular complicatons. Hypertension 1985; 7: Suppl. 2: 125–130.Google Scholar
  70. 70.
    Tzamaloukas AH, Rogers K, Ferguson BJ, Leymon PC, Sena P, Merlin TL, Avasthi PS. Management of diabetics on CAPD with subcutaneous insulin. Adv Perit Dial 1988; 4: 126–132.Google Scholar
  71. 71.
    Diaz-Buxo JA, Burgess WP, Greenman M, Chandler JT, Farmer CD, Walker PJ. Visual function in diabetic patients undergoing dialysis: comparison of peritoneal and haemodialysis. Int J Artif Organs 1984; 7: 257–262.PubMedGoogle Scholar
  72. 72.
    Catalano C, Goodship THJ, Tapson TS, Venning MK, Taylor RMR, Proud G, Tunbridge WM, Elliot RW, Ward MK, Alberti KGMM, Wilkinson R. Renal replacement therapy for diabetic patients in Newcastle-upon-Tyne and northern region, 1964–1988. BMJ 1990; 301: 535–540.PubMedGoogle Scholar
  73. 73.
    Brown PM, Johnston KW, Fenton SA, Cattran DC. Symptomatic exacerbation of peripheral vascular disease with chronic ambulatory peritoneal dialysis. Clin Nephrol 1981; 16: 258–261.PubMedGoogle Scholar
  74. 74.
    Tzamaloukas AH, Murata GH, Harford AM, Sena P, Zager PG, Eisenberg B, Wood B, Simon D, Goldman RS, Kanig SP, Avasthi PS, Saddler MC. Hand gangrene in diabetic patients on chronic dialysis. ASAIO Trans 1991; 37: 638–643.PubMedGoogle Scholar
  75. 75.
    LoGerfo FW, Gibbons GW. »Vascular disease of the lower extremites in diabetes mellitus: Etiology and management.« In Joslin’s Diabetes Mellitus, 13th ed, Kahn CR, Weir GC, eds. Philadelphia: Lea and Febiger, 1994; pp 970–975.Google Scholar
  76. 76.
    Levin ME. The diabetic foot: A primer for nephrologists. Sem Dial 1991; 4: 258–264.Google Scholar
  77. 77.
    Khanna R, Wu G, Prowant B, Jastrzebska J, Nolph KD, Oreopoulos DG. »Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease: A combined experience of two North American centers.« In Diabetic Renal-Retinal Syndrome 3, Friedman E, L’Esperance F, eds. New York: Grune and Stratton, 1986; pp 363–381.Google Scholar
  78. 78.
    Coronel F, Tornero F, Macia M, Sanche A, De Oleo P, Naranjo P, Barrientos A. Peritoneal clearances, protein losses and ultrafiltration in diabetic patients after four years on CAPD. Adv Perit Dial 1991; 7: 35–38.PubMedGoogle Scholar
  79. 79.
    Lee HB, Park MS, Chung SH, Lee YB, Kim KS, Hwang SD, Moon C. Peritoneal solute clearances in diabetics. Perit Dial Int 1990; 10: 85–88.PubMedGoogle Scholar
  80. 80.
    Johnston JR, Bernardini J, Holley J, Piraino B. Effect of increasing exchange volume or frequency on CAPD efficiency. Adv Perit Dial 1995; 11: 97–100.PubMedGoogle Scholar
  81. 81.
    Lindblad AS, Novak JW, Nolph KD. Continuous Ambulatory Peritoneal Dialysis in the USA. Final report of the National CAPD registry 1981–1988. Dordrecht: Kluwer Academic Publishers, 1989; pp 30, 37, 258.Google Scholar
  82. 82.
    Lindblad AS, Nolph KD, Novak JW, Friedman EA. A survey of the NIH CAPD Registry population with end-stage renal disease attributed to diabetic nephropathy. J Diabetic Compl 1988; 2: 227–232.Google Scholar
  83. 83.
    Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, Wone C, Knefati Y, Kessler M, Peluso F. Staphylococcus aureus carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322: 505–509.PubMedGoogle Scholar
  84. 84.
    Holley JL, Bernardini J, Piraino B. Risk factors for tunnel infections in continuous peritoneal dialysis. Am J Kidney Dis 1991; 18: 344–348.PubMedGoogle Scholar
  85. 85.
    Tuazon CU. Staphylococcus aureus among insulin-injecting diabetic patients: An increased carried rate. JAMA 1975; 231: 1272.PubMedGoogle Scholar
  86. 86.
    Heimburger O, Bergstrom J, Lindholm B. Maintenance of optimal nutrition in CAPD. Kidney Int 1994; 46: Suppl. 48: S39–S46.Google Scholar
  87. 87.
    Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. Nephron 1986; 42: 133–140.PubMedGoogle Scholar
  88. 88.
    Young CA, Kopple JD, Lindholm B, De Vecchi A, Scalamogna A, Castelnova C, Oreopoulos DG, Anderson GH, Bergstrom J, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17: 462–471.PubMedGoogle Scholar
  89. 89.
    Marckmann P. Nutritional status of patients on haemodialysis and peritoneal dialysis. Clin Nephrol 1988; 29: 75–78.PubMedGoogle Scholar
  90. 90.
    Jones M, Hamburger R, Charytan C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, et al. Treatment of malnutrition in peritoneal dialysis (PD) patients with a 1.1% amino-acid (AA) dialysis solution (Abstract). Perit Dial Int 1995; 15: Suppl. 1: S42.Google Scholar
  91. 91.
    Appel G. Nephrology forum: Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–183.PubMedGoogle Scholar
  92. 92.
    Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dislipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20: 324–335.PubMedGoogle Scholar
  93. 93.
    Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993, 21: 573–592.PubMedGoogle Scholar
  94. 94.
    Keane WF. Lipids and the kidney. Kidney Int 1994; 46: 910–920.PubMedGoogle Scholar
  95. 95.
    Cheung AK, Wu LL, Kablitz C, Leypoldt JK. Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 1993; 22: 271–276.PubMedGoogle Scholar
  96. 96.
    Appel GB. How should the lipid abnormalities of dialysis patients be treated? Sem Dial 1995; 8: 15–16.Google Scholar
  97. 97.
    Jacobs C. How should the lipid abnormalities of dialysis patients be treated? Sem Dial 1995; 8: 17–19.Google Scholar
  98. 98.
    Markell MS. How should the lipid abnormalities of dialysis patients be treated? Sem Dial 1995; 8: 19–21.Google Scholar
  99. 99.
    Iaina A, Weintraub M. How should the lipid abnormalities of dialysis patients be treated? Sem Dial 1995; 8: 21–22.Google Scholar
  100. 100.
    Balaskas EV, Bamihas GI, Karamouzis M, Sioulis A, Tourkantonis A. Gemfibrozil treatment of hypertriglyceridemia in CAPD patients. Perit Dial Int 1996; 16: Suppl. 2: S57.Google Scholar
  101. 101.
    Balaskas EV, Bamihas GI, Pidonia I, Gutsaridis N, Tourkantonis A. The effect of Pravastatin on hyperlipaemia in CAPD patients. Perit Dial Int 1996; 16: Suppl. 2: S58.Google Scholar
  102. 102.
    Balaskas EV, Bamihas GI, Pidonia I, Giousef H, Tourkantonis A. Omega-3 fatty acids in the management of dyslipaemia in CAPD patients. Perit Dial Int 1996; 16: Suppl. 2: S58.Google Scholar
  103. 103.
    Burton PR, Walls J. A selection adjusted comparison of hospitalization on continuous ambulatory peritoneal dialysis and haemodialysis. J Clin Epidemiol 1989; 42: 531–539.PubMedGoogle Scholar
  104. 104.
    Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: A multicenter study. Perit Dial Int 1990; 10: 15–19.PubMedGoogle Scholar
  105. 105.
    Bloembergen WE, Port FK, Mauger EA, Wolf RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 184–191.PubMedGoogle Scholar
  106. 106.
    Chandran PKG, Lane T, Flynn CT. Patient and technique survival for blind and sighted diabetics on continuous ambulatory peritoneal dialysis: a ten years analysis. Int J Artif Organs 1991; 14: 262–268.PubMedGoogle Scholar
  107. 107.
    Brunner FP. End-stage renal failure due to diabetic nephropathy: data from the EDTA registry. J Diabetic Compl 1989; 3: 127–135.Google Scholar
  108. 108.
    Hamburger RJ, Mattern WD, Schreiber MJ, Doerblom R, Sorkin M, Zimmerman SW. A dialysis modality decision guide based on the experience of six dialysis centers. Dial Transplant 1990; 19: 66–69.Google Scholar
  109. 109.
    Gokal R, Friedman EA, Rottembourg J, Tzamaloukas AH, Beeker GJ. Peritoneal dialysis in diabetic ESRD patients. Dial Transplant 1991; 20: 59–66.Google Scholar
  110. 110.
    Wolfe RA, Port FK, Hawthorne VM, Guire KE. A comparison of survival among dialytic therapies of choice: in-center haemodialysis versus continuous ambulatory peritoneal dialysis at home. Am J Kidney Dis 1990; 15: 433–440.PubMedGoogle Scholar
  111. 111.
    U.S. Renal Data System. USRDS 1991 Annual Data Report. Bethesda. NIH; August 1991; D.38, D.40, E.56, E.57.Google Scholar
  112. 112.
    Nelson CB, Port FK, Wolfe RA, Guire KE. Comparison of continuous ambulatory peritoneal dialysis and haemodialysis patient survival with evaluation of trends during the 1980s. J Am Soc Nephrol 1992; 3: 1147–1155.PubMedGoogle Scholar
  113. 113.
    Nelson CB, Port FK, Wolfe RA, Guire KE. Dialysis patient survival: Evaluation of CAPD vs HD using 3 techniques (Abstract). Perit Dial Int 1992; 12: Suppl. 1: 144.Google Scholar
  114. 114.
    Bloembergen WE, Port FK, Mauger EA, Wolf RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 177–183.PubMedGoogle Scholar
  115. 115.
    Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med 1993; 329: 1035–1036.PubMedGoogle Scholar
  116. 116.
    Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.Google Scholar
  117. 117.
    Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315–1321.PubMedGoogle Scholar
  118. 118.
    Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 33: 1–34.Google Scholar
  119. 119.
    Vlassara H. Advanced glycation in diabetic renal and vascular disease. Kidney Int 1995; 48: Suppl. 51:S43–S44.Google Scholar
  120. 120.
    Makita Z. Toxicity of glucose: is AGE the answer? Nephrol Dial Transplant 1995; 10: Suppl. 7: 33–37.PubMedGoogle Scholar
  121. 121.
    Williams ME. Dam (AGE) in diabetic ESRD: Role of advanced glycosylation. Sem Dial 1996; 9: 1–4.Google Scholar
  122. 122.
    Vlassara H. Recent progress on the biological and clinical significance of advanced glycosylation end-products. J Lab Clinic Med 1994; 124: 19–30.Google Scholar
  123. 123.
    Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degredation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5588–5592.PubMedGoogle Scholar
  124. 124.
    Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavanger receptors. J Exp Med 1986; 164: 1301–1309.PubMedGoogle Scholar
  125. 125.
    Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 1991; 325; 836–842.PubMedGoogle Scholar
  126. 126.
    Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267: 5133–5138.PubMedGoogle Scholar
  127. 127.
    Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. Reactive glycosylation end-products in diabetic uremia and treatment of renal failure. Lancet 1994; 343: 1519–1522.PubMedGoogle Scholar
  128. 128.
    Korbet SM, Makita Z, Friedman EA, Vlassra H. Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1993; 22: 588–591.PubMedGoogle Scholar
  129. 129.
    Lamb EJ, Cattell WR, Dawnay AB St. J. In vitro formation of advanced glycasion end products in peritoneal dialysis fluid, Kidney Int 1995; 47: 1768–1774.PubMedGoogle Scholar
  130. 130.
    Makita Z, Vlassara H, Rayfield EJ, Cartweight K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651–653.PubMedGoogle Scholar
  131. 131.
    Friedman MA, Wu YC, James MS, Schulak A, Monnier VM, Hrielk DE. Influence of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445–451.Google Scholar
  132. 132.
    Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidines. Diabetes 1992; 41: 26–29.PubMedGoogle Scholar
  133. 133.
    Yagihashi S, Kamijo M, Baba M, Yagihashi N, Najai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of stz-induced diabetic rats. Diabetes 1992; 41: 47–52.PubMedGoogle Scholar
  134. 134.
    Chibber R, Molinatti PA, Wong JSK, Mirlees D, Kohner EM. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes 1994; 43: 758–763.PubMedGoogle Scholar
  135. 135.
    Brownlee M, Vlassara H, Kooney P, Ulrich A, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629–1632.PubMedGoogle Scholar
  136. 136.
    Brownlee M. Glycation and diabetic complications. Diabetes 1994; 43: 837–841.Google Scholar
  137. 137.
    Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328–1334.PubMedGoogle Scholar
  138. 138.
    Abraham G, Zlotnik N, Ayiomamitis A, Oreopoulos DG. Drop-out of diabetic patients from CAPD. Adv Perit Dial 1987; 3: 199–204.Google Scholar
  139. 139.
    Rubin J, Hsu H. Continuous ambulatory peritoneal dialysis: ten years at one facility. Am J Kidney Dis 1991; 17: 165–169.PubMedGoogle Scholar
  140. 140.
    Schmitz O, Mogensen CE. How can the care of diabetic ESRD patients be improved? Sem Dial 1991; 4: 24–25.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Elias V. Balaskas
    • 1
  • Dimitrios G. Orepoulos
    • 1
  1. 1.Peritoneal Dialysis UnitUniversity of Toronto, The Toronto HospitalTorontoCanada

Personalised recommendations